PetMeds CEO Transition: Jeff Willard To Succeed Leslie Campbell

PetMed Express (PETS) named Jeff Willard as CEO and President, effective September 28, 2026. Willard succeeds Leslie Campbell, who will retire as Board Chair. Willard has 25 years of leadership experience in consumer and e-commerce. The company aims to return to profitability and growth. PETS stock traded between $1.57 and $4.10 in the past year, closing at $4.10 on Wednesday.

Original reporting
Published Sep 17, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 2:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$PETS
Neutral
medium confidence
Mentioned
$PETS · $CPB
Relevance
6/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$PETSNeutralLow
01

Why it matters

The appointment of Jeff Willard, with extensive e‑commerce experience, aims to drive operational execution and return to sustainable profitability.

02

Market read

Leadership change is the primary catalyst; investors may reassess valuation based on Willard's track record.

03

What to watch

Potential integration issues with subsidiary PetCareRx and competitive pressure from larger pet‑care chains.

Relevance 6/10Novelty 6/10Timing: pre-market today

Background

PetMeds (PETS) is a direct‑to‑consumer pet‑healthcare company operating an online pharmacy. The stock has been volatile, trading $1.57‑$4.10 over the past year.

Company-level read

Ticker impact

$PETSNeutralMedium confidence
Context

PetMeds announced Jeff Willard as new CEO and President effective Sep 28, 2026, replacing interim CEO Leslie Campbell.

Expected impact

Potential short-term upside as investors assess new CEO's track record; medium-term impact depends on execution.

Evidence & confidence

Exec transition is a primary disclosure but limited to leadership; no immediate financial metrics disclosed.

Market effects

May signal renewed focus on profitability for the pet healthcare e‑commerce sector.

Limited to US-listed pet‑care retail segment.

Minimal global impact beyond niche pet‑care investors.

Counterpoint

New CEO could struggle to reverse growth challenges, leading to further downside.

Key entities

  • Jeff Willard

    New CEO and President of PetMeds.

  • Leslie C.G. Campbell

    Outgoing interim CEO and Board Chair.

Related articles

$PETSMed

PetMed Express Inc (PETS) (Q2 2027) Earnings Call Highlights: New CEO Charts

PetMed Express (PETS) reported Q2 2027 net sales of $35.8M, down 19.4% YoY, with a net loss of $6.4M. New CEO Jeff Willard highlighted cost reductions, including a 32% drop in customer acquisition cost and a 52.3% cut in advertising expenses. The company has $11.4M in cash and no debt. Willard outlined a multiyear turnaround strategy focusing on brand repositioning, marketing efficiency, and customer retention. Gross margin fell to 27.4% due to product mix and lower rebates.